Thus, given the conflicting data discussed above and the uncertainty over the beneficial renal effects of PPAR agonists in different mouse models, as well as the limited studies of renoprotection particularly in the BTBRob/ob model of DN, we wanted to investigate the effect of a dual PPARα/γ agonist, AZD6610, and compare it with RAS blockade using the ACE inhibitor enalapril, starting treatment at 17 weeks of age when the mice consistently show features of DN. Here, PPARA is linked to liver dysplastic nodule.